コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 experiments with 5-hydroxy-L-tryptophan and serotonin.
2 , an enzyme associated with the synthesis of serotonin.
3 synthesizes the vast majority of the body's serotonin.
4 brain neuromodulators, such as oxytocin and serotonin.
5 ased on immunostainings against synapsin and serotonin.
6 e of serotonin, which in turn impacts on the serotonin 1A receptor system, by modulating its availabi
7 cohort also underwent (11)C-WAY100635 scans (serotonin-1A receptor [5-HT1A]), we examined whether usi
9 ned and synthesized, with the aim of finding serotonin 2C (5-HT2C)-selective agonists with a preferen
14 fied in this work supports the interest of a serotonin 5-HT2CR PAM as a promising therapeutic approac
17 ing preclinical evidence has implicated both serotonin (5-HT) 2C and 2A receptors as potential mechan
18 g laying-defective and contain low levels of serotonin (5-HT) and high levels of the 5-HT metabolite
19 Caenorhabditis elegans, the biogenic amines serotonin (5-HT) and octopamine regulate a number of foo
20 sour sensing cells, Type III cells, release serotonin (5-HT) in response to the presence of sour (ac
23 STATEMENT The modulation of the amygdala by serotonin (5-HT) is important for emotional regulation a
25 at Necdin deletion disturbs the migration of serotonin (5-HT) neuronal precursors, leading to altered
27 taining monoamines such as dopamine (DA) and serotonin (5-HT) occur in the periventricular zones of t
29 ine (OA) receptor, OCTR-1, and a 5-HT1A-like serotonin (5-HT) receptor, SER-4, that involves a comple
31 ated SERT Ala56 variant have altered central serotonin (5-HT) system function, as well as elevated pe
32 encoding the integrin beta3 subunit with the serotonin (5-HT) system, likely via its modulation of th
33 stigated a widely distributed CNS modulator, serotonin (5-HT), for its ability to modulate the biophy
36 drugs (APDs) target primarily dopamine D2 or serotonin (5-HT2A) receptors, or both; however, these me
38 deaths are associated with abnormalities in serotonin (5-hydroxytryptamine, 5-HT) in regions of the
42 thelium is the source of nearly all systemic serotonin (5-hydroxytryptamine; 5-HT), which is an impor
44 aviors were accompanied by striatal dopamine/serotonin abnormalities and cortical excitation-inhibiti
45 e, gamma-aminobutyric acid (GABA), dopamine, serotonin, acetylcholine and opioids-and numerous ion ch
46 ne at spinal alpha2 -adrenoceptors, although serotonin, acting on facilitatory spinal 5-HT3 receptors
49 a U.S. Food and Drug Administration-approved serotonin agonist (lorcaserin) to septic rats greatly im
50 before and after treatment with psilocybin (serotonin agonist) for treatment-resistant depression (T
54 rthermore, by comparing the cue responses of serotonin and dopamine neurons, we found differences in
55 r accumulation of neurotransmitters, such as serotonin and dopamine, in insulin storage granules in p
56 l transduction, G protein coupled receptors, serotonin and glycosaminoglycan metabolisms among others
59 rainstem neurons that release the monoamines serotonin and noradrenaline, and local vessel dilation i
60 ly prescribed antidepressant, is a selective serotonin and norepinephrine reuptake inhibitor in human
61 T and a higher selectivity toward DAT versus serotonin and norepinephrine transporters than modafinil
62 TRIs), which elevate dopamine in addition to serotonin and norepinephrine, may demonstrate greater ef
63 nvestigated the roles of the biogenic amines serotonin and octopamine in regulating locomotion behavi
64 ght both a specific function in learning for serotonin and the importance of studying its role across
65 rethral neuroendocrine cells expressing both serotonin and YFP, whereas single serotonin labeling was
67 easurements of neurotransmitters (melatonin, serotonin, and epinephrine) at various concentrations fo
68 monoaminergic systems, notably dopamine and serotonin, and integrates cognitive with emotional and s
69 t, with one exception, monoamines (dopamine, serotonin, and norepinephrine) signal via metabotropic r
71 the monoamine neurotransmitters dopamine and serotonin, and suffer a multi-systemic disorder characte
73 hemical double labeling studies with YFP and serotonin antisera combined with electron microscopy wer
79 ependently converged on the observation that serotonin binds well within the insulin hexamer (site I)
80 that not all immunoreactive neurons produce serotonin, but have the capability for serotonin uptake.
82 We show that three gastrointestinal signals-serotonin, CCK, and PYY-are necessary or sufficient for
83 tide in proportion to fluctuations in neural serotonin circuit functions, and its release is regulate
86 es a significant contribution to circulating serotonin concentrations during lactation, with no effec
87 WAP-Cre x Lrp5 (FL/FL) dams had elevated serotonin concentrations in both the mammary gland and c
94 nticipate that investigation of dopamine and serotonin disturbances will be facilitated by measuremen
96 synthesized, and evaluated as ligands of 34 serotonin, dopamine, histamine, melatonin, acetylcholine
98 hich exhibited dose-dependent enhancement of serotonin efficacy, no significant off-target activities
99 dentifies a simple computational function of serotonin for state-dependent sensory processing, depend
100 ts latent effects of early life adversity on serotonin function may play a role in this phenomenon.
104 ed neurons, the "contralaterally projecting, serotonin-immunoreactive deutocerebral neurons" (CSDns),
105 the morphology of individually identifiable serotonin-immunoreactive neurons in the ventral nerve co
106 raconata contains a comparably low number of serotonin-immunoreactive neurons, facilitating individua
112 physiological or pathophysiological roles of serotonin in tissues where 5-HT2 receptors are co-expres
115 f TPH2 immunoreactivity and largely preserve serotonin innervation of motor neurons in the spinal cor
116 e investigated mechanisms by which GLP-1 and serotonin interact at the level of the central nervous s
117 reduce body weight in rats, suggesting that serotonin is a critical mediator of the energy balance i
119 r, chronic exposure to excessive circulating serotonin is considered one of the most important contri
123 n the awake macaque the modulatory effect of serotonin is surprisingly uniform: it causes a mainly mu
124 ssing both serotonin and YFP, whereas single serotonin labeling was observed in 36% and exclusive YFP
125 xamine effects on blood, placenta and embryo serotonin levels and neurodevelopment at embryonic day E
127 ly reduced concentrations of brain dopamine, serotonin levels were markedly diminished, and this pert
130 1b, which encodes an enzyme that synthesizes serotonin, mark a subpopulation of fibroblast-like cells
131 ered in neuropathy and the effects of excess serotonin may now become inhibitory through activation o
133 :Nth1 complex structure with those of 14-3-3:serotonin N-acetyltransferase and 14-3-3:heat shock prot
139 r findings show how the activity patterns of serotonin neurons support a role in cognitive flexibilit
141 ant SOD1 expression selectively in brainstem serotonin neurons was sufficient to rescue loss of TPH2
142 n mice to study a population of dorsal raphe serotonin neurons, whose activity we could link to norma
145 lities in central oxytocin, vasopressin, and serotonin neurotransmission, and neuroinflammation.
147 gastrointestinal pain and painful FGIDs and serotonin noradrenergic reuptake inhibitors can also be
148 t associated with treatment outcomes for the serotonin norepinephrine reuptake inhibitor venlafaxine.
149 l prescriptions for a selective serotonin or serotonin-norepinephrine reuptake inhibitor between conc
150 orded selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor prescription
151 from selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor use and 11 s
152 y ill selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor users, but u
154 ctive serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), an
155 ive serotonin reuptake inhibitors [SSRIs] or serotonin-norepinephrine reuptake inhibitors [SNRIs], tr
158 se of selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitors previously
159 tient selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitors were contin
161 ity, and suggest a revised model of dopamine-serotonin opponency with potential clinical implications
164 utive maternal prescriptions for a selective serotonin or serotonin-norepinephrine reuptake inhibitor
165 eurogenin 3 (NEUROG3), chromogranin A (CgA), serotonin, peptide YY (PYY), oxyntomodulin (enteroglucag
168 Dorsal raphe (DR) harbors cell bodies of serotonin-producing neurons that supply serotonin to the
170 ypes: alpha7-nAChR, alpha4beta2-nAChR, and a serotonin receptor (5-HT3AR), along with a fluorescent r
171 tophan hydroxylase 1 (Tph1, rs262731280) and serotonin receptor 3A (Htr3a, rs50670893) were associate
173 ase inhibitor) and pergolide (a dopamine and serotonin receptor agonist) robustly reduced alcohol int
174 y was used to advance the novel concept that serotonin receptor subtype 5-HT2C contributes critically
175 nputs from the basolateral nucleus (BLA) and serotonin receptor subtype 5-HT2CR in the BLA, but not C
180 rtex of Phf8 deficient mice and identify the serotonin receptors Htr1a and Htr2a as direct targets of
181 roxytryptamine (5-HT) 2A (5-HT2A) and 5-HT2C serotonin receptors in the hypothalamus were altered by
182 previously that pharmacologic activation of serotonin receptors on motor neurons increases motor neu
183 RETATION: Our findings suggest activation of serotonin receptors with lorcaserin may provide the firs
184 d agonists for members of the 5-HT2 class of serotonin receptors, 2,5-dimethoxy-4-iodoamphetamine (DO
185 The prototypical hallucinogen LSD acts via serotonin receptors, and here we describe the crystal st
187 ics in offspring of mothers with deficits in serotonin related pathways during stressful pregnancies.
188 ockdown decreases mechanosensitive currents, serotonin release and downstream physiological effects.
189 A total of 11 patients (8.1%) had positive serotonin release assay and 80 patients had positive ant
191 eparin enzyme-linked immunosorbent assay and serotonin release assay testing between January 1, 2011,
194 serotonin acts on its cellular targets, how serotonin release is regulated in vivo remains poorly un
195 waning of serum-induced heparin-independent serotonin release) with successful outpatient rivaroxaba
197 oamine-releaser with particularly pronounced serotonin- releasing properties, has unique subjective e
199 ntidepressants that are strong inhibitors of serotonin reuptake actually increase the risk for ICH an
200 of antidepressants with strong inhibition of serotonin reuptake are associated with an increased risk
201 sant medication or specifically to selective serotonin reuptake inhibitor (SSRI) antidepressants, all
204 we show that when the effects of a selective serotonin reuptake inhibitor (SSRI, citalopram) are stud
209 ion was shortened by 3.6 days; with maternal serotonin reuptake inhibitor use, gestation was shortene
210 For SERT analysis, patients on selective serotonin reuptake inhibitor were excluded (n = 48 remai
212 reatment of Hoxb8 mutants with fluoxetine, a serotonin reuptake inhibitor, reduces excessive grooming
213 excess morbidity in critically ill selective serotonin reuptake inhibitor/serotonin-norepinephrine re
215 case report suggested benefit from selective serotonin reuptake inhibitor/serotonin-norepinephrine re
216 dies of ICU patients with recorded selective serotonin reuptake inhibitor/serotonin-norepinephrine re
217 as generally unclear if outpatient selective serotonin reuptake inhibitor/serotonin-norepinephrine re
218 exposed and control groups; use of selective serotonin reuptake inhibitor/serotonin-norepinephrine re
220 ors, both of which are reversed by selective serotonin reuptake inhibitors (SSRIs) and the tricyclic
224 he relative efficacy and safety of selective serotonin reuptake inhibitors (SSRIs), serotonin-norepin
227 inhibitors, patients taking higher doses of serotonin reuptake inhibitors and who had a longer durat
228 ce continues to support the use of selective serotonin reuptake inhibitors as first-line pharmacologi
229 ponded significantly better to the selective serotonin reuptake inhibitors escitalopram and sertralin
230 gether with the demonstrated efficacy of the serotonin reuptake inhibitors for childhood-onset obsess
231 The efficacy and adverse events of selective serotonin reuptake inhibitors in these patients are unkn
232 setron) either in combination with selective serotonin reuptake inhibitors or as monotherapy in the t
233 behavioral therapy with or without selective serotonin reuptake inhibitors remains a preferred initia
235 year risk of MOF by 36% for use of selective serotonin reuptake inhibitors, by 63% for use of mood st
236 of hip fracture by 57% for use of selective serotonin reuptake inhibitors, by 98% for use of mood st
237 Compared with patients who were not taking serotonin reuptake inhibitors, patients taking higher do
238 used to examine the effect of treatment with serotonin reuptake inhibitors, with or without antipsych
243 -current stimulation (tDCS) with a selective serotonin-reuptake inhibitor for the treatment of depres
247 rs, are electrically excitable, and modulate serotonin-sensitive primary afferent nerve fibers via sy
251 activity can be mimicked by drugs acting on serotonin signalling pathways e.g. trazodone and lorcase
253 sh a direct link between Phf8 expression and serotonin signalling, identifying this histone demethyla
254 stent with low basal occupancy by endogenous serotonin.SIGNIFICANCE STATEMENT We here show that combi
256 function in other genes in the dopamine and serotonin synthesis pathways did not alter tau-induced t
262 imaging with a radiotracer specific for the serotonin transporter (5-HTT), (11)C-McN5652, we found t
264 lthio)benzylamine ((11)C-HOMADAM) imaging of serotonin transporter (SERT) density in healthy control
266 t years, a number of PET studies imaging the serotonin transporter (SERT) have been used and provided
267 oimaging, and genetic findings implicate the serotonin transporter (SERT) in autism spectrum disorder
270 n, (123)I-FP-CIT has modest affinity for the serotonin transporter (SERT), predominantly represented
272 norepinephrine transporter (SLC6A2, NET) and serotonin transporter (SLC6A4, SERT) genes and remission
273 18)F]MPPF, two PET radiotracers, marking the serotonin transporter and the 5-HT1AR, respectively.
274 ative affinity of the antidepressant for the serotonin transporter and to assess whether concomitant
275 May, 2016, were studied with tracers for the serotonin transporter and vesicular monoamine transporte
276 ding, VMAT2 binding, (18)F-FDOPA uptake, and serotonin transporter binding in multiple brain regions
278 rkinson's disease had significantly elevated serotonin transporter binding in the hypothalamus (compa
279 manifest Parkinson's disease show increased serotonin transporter binding in the striatum, brainstem
280 ng PET, we assessed whether dopaminergic and serotonin transporter changes are similar in LRRK2 mutat
282 entifying two common genetic variants of the serotonin transporter gene and their association with in
284 igates whether a genetic polymorphism of the serotonin transporter gene moderates susceptibility to a
285 methylation of the proximal promoter of the serotonin transporter gene, which predicts greater incre
289 hypothesis that the S allele of the 5-HTTLPR serotonin transporter promoter region is associated with
290 was no association between genotypes of the serotonin transporter promoter region polymorphism and s
292 f the maternal polymorphism, 5HTTLPR, in the serotonin transporter, SLC6A4, coupled with prenatal str
296 gonist quinpirole, but not norepinephrine or serotonin, was prevented by the GABAA receptor antagonis
297 GWamide, DLamide, FLamide, FVamide, MIP, and serotonin were present in fewer cells in demarcated regi
298 found that oxytocin provokes the release of serotonin, which in turn impacts on the serotonin 1A rec
299 e the oxidation and recovery of dopamine and serotonin, while transmission spectrum measurement was c
300 itters-gamma-aminobutyric acid, dopamine and serotonin-with high spectroscopic confidence in the mous
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。